KR20120003693A - Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine - Google Patents

Abstract

PURPOSE: An anti-obesity composition containing extract of green tea, soybeans, and red grapes and L-carnitine is provided to treat fatty liver. CONSTITUTION: An anti-obesity composition contains extract of green tea, soybeans, or red grapes, and L-carnitine as an active ingredient. The red grape and soybean extract contains resveratrol and isoflavone. The green tea extract is isolated from green tea leaves using purified water. The red grape extract is isolated from red grape cover using ethanol. The soybean extract is isolated from soybean germ using purified water. A pharmaceutical composition for preventing or treating obesity or fatty liver contains the anti-obesity composition. The pharmaceutical composition is manufactured in the form of a tablet, pill, powder, granule, capsule, suspension, emulsion, syrup, or aerosol.

Description

Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and L-carnitine as red ginseng extract, green tea extract, soybean extract and L-carnitine as active ingredients

The present invention relates to an anti-obesity composition, and more particularly to an anti-obesity composition containing one or more selected from the group consisting of green tea extract and soybean extract and red grape extract and L-carnitine as an active ingredient. The present invention exhibits excellent anti-obesity effects such as weight loss, blood lipid concentration reduction, body fat reduction and blood leptin concentration, as well as hepatic lipid deposition reducing effects, thereby improving obesity-related diseases.

Obesity is a phenomenon in which excess energy is accumulated as body fat due to an imbalance between energy consumed by food and energy consumed by physical activity. In general, obesity refers to a condition in which the adipose tissue is excessive in the body, and if the obesity condition persists for a long time, various metabolic diseases and adult diseases such as diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, fatty liver, and the like are induced. Recently, obesity has been increasing not only in western developed countries but also in Korea due to excessive calorie intake and lack of exercise, which is a serious social problem.

Obesity is known to be caused by excess energy supply causing fat cell size and number to accumulate in the body fat. In addition, genetic factors, environmental factors caused by Western diets, psychological factors, energy metabolism It is known that various causes such as the above work.

Research on various aspects of the development of anti-obesity drugs is underway worldwide. Obesity medications can be divided into mechanisms to suppress fat absorption, promote fat breakdown and heat generation, regulate appetite and satiety, inhibit protein metabolism and affect food intake. Representative anti-obesity agent is a rideoktil ^™ (Reductil ^™) to stimulate the sympathetic nervous system as Xenical ^™ (Xenical ^™) as the main ingredient of sibutramine in the oristat as a raw material suppresses fat absorption inhibiting appetite. However, Xenical ^™ jibangbyeon, reason, and reported side effects such as abdominal pain, vomiting, itching, liver damage, if rideoktil ^™, headache, loss of appetite, insomnia, as a side effect of constipation as causing serious cardiovascular side effects Recently, there is a controversy over the use of standards. In addition to the drug therapy through the treatment of obesity, there is a diet to limit the intake of food, exercise therapy to increase the energy consumption as a method for preventing and treating obesity, psychotherapy, behavioral therapy, surgical therapy, and the like.

As a preferred method of treating obesity, promoting energy consumption through exercise and combining obesity treatment drugs with fewer side effects have been suggested as the safe and effective method. However, in the case of drugs for the treatment of obesity, serious side effects have been reported, as in the examples of XENNITAL ^™ and REDUCTIL ^™ , and there is no clear trust in safety. Therefore, there is a need for the development of a material that is 100% safe while showing excellent efficacy of anti-obesity for the human body. Recently, various studies on obesity treatment materials have been conducted through the mechanism of fat burning / decomposing in vivo and the mechanism of promoting energy metabolism, and above all, functional foods based on materials that can ensure safety for the human body. It is a situation that needs to be developed.

Accordingly, the present inventors have a composition containing at least one selected from the group consisting of green tea extract and soybean extract and red grape extract and L-carnitine as an active ingredient weight loss, blood lipid concentration, body fat reduction and blood As well as excellent anti-obesity effect, such as reducing leptin concentration, it has been confirmed that it has excellent efficacy in improving various obesity-related diseases as well as reducing liver lipid deposition.

An object of the present invention is to provide an anti-obesity composition containing at least one selected from the group consisting of green tea extract and soybean extract and red grape extract and L-carnitine as an active ingredient.

An object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity or fatty liver comprising the anti-obesity composition.

An object of the present invention is to provide a food composition for preventing or improving obesity or fatty liver comprising the anti-obesity composition.

In one embodiment, the present invention relates to an anti-obesity composition containing at least one selected from the group consisting of green tea extract and soybean extract and red grape extract and L-carnitine as an active ingredient.

The inventors have provided a composite composition comprising grape extract, green tea extract and L-carnitine, a composite composition comprising grape extract, soybean extract and L-carnitine, and a composite comprising grape extract, green tea extract, soybean extract and L-carnitine. It was confirmed that the composition has an anti-obesity effect. In particular, the inventors have provided a combination composition comprising red grape extract, green tea extract and L-carnitine, a composite composition comprising red grape extract, soybean extract and L-carnitine, and red grape extract, green tea extract, soybean extract and L- It was confirmed that there is an anti-obesity effect on the composite composition containing carnitine.

More specifically, the present inventors mixed and administered one or more selected from the group consisting of red grape extract, green tea extract, soybean extract and L-carnitine in various combinations, the red grape extract, green tea extract, soybean extract and L- A composition containing all carnitine (Example 1, Treatment Group 1) and a composite composition (Example 2, Treatment Group 2) comprising red grape extract, green tea extract, and L-carnitine, red grape extract, soybean extract, and L- Excellent weight loss effect (Experimental Example 1), blood lipid concentration reduction effect (Experimental Example 2), liver tissue and body fat reduction effect (Experimental Example 3), plasma in a composite composition containing carnitine (Example 3, Treatment Group 3) The effect of reducing the concentration of glucose in the liver, improving the liver lipids, and inhibiting leptin secretion (Experimental Example 4) was confirmed. In particular, it showed excellent anti-obesity effect in the composition which mixed all four substances.

In contrast, red grape extract (Comparative Example 5, Treatment Group 8), green tea extract (Comparative Example 6, Treatment Group 9), soybean extract (Comparative Example 7, Treatment Group 10), and L-carnitine (Comparative Example 8, treatment Group 11) a single composition containing each alone, a composite composition containing red grape extract and green tea extract (Comparative Example 2, treatment group 5), a composite composition containing red grape extract and soy extract (Comparative Example 3, treatment Group 6), and a composite composition containing red grape extract and L-carnitine (Comparative Example 4, treated group 7), and a composite composition comprising red grape extract, green tea extract and soybean extract (Comparative Example 1, treated group 4). ) Had a minimal anti-obesity effect.

Thus, the present inventors compared the anti-obesity effect of the single composition or the composite composition of the two substances as well as the combination composition of the other three substances, grape extract, green tea extract (or / and soybean extract), and L- It has been found that a composite composition comprising carnitine has a significant anti-obesity effect, and the composite composition of the grape extract, green tea extract (or / or soybean extract), and L-carnitine of the present invention is a grape extract, green tea extract (or / And soybean extract), and L-carnitine showed a strong synergistic effect, showing a significantly increased anti-obesity effect even when contained in a small concentration.

As used herein, the term 'anti-obesity composition' refers to a composition exhibiting at least one effect of weight loss, decreased blood lipid concentration, reduced liver tissue and body fat, reduced plasma glucose concentration, improved liver lipid, and inhibition of leptin secretion. The anti-obesity composition can be used to ameliorate, prevent, or treat obesity-related diseases, that is, various metabolic diseases such as diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis, fatty liver, and the like derived from obesity and obesity.

In the present invention, the 'grape extract' can be extracted from various organs of natural, hybrid, mutant plants, for example from bark, seeds as well as plant tissue cultures. Grape extracts can be prepared using various solvents by various methods known in the art, and may be purified water, methanol, ethanol, propanol, butanol, ethylene glycol, propylene glycol, 1,3-butylene glycol, ethyl acetate, acetone. One or two or more solvents selected from the composed crowd may be mixed and extracted, preferably using 5 to 100% ethanol, and more preferably 70% ethanol. According to a specific embodiment of the present invention, red grape extract was obtained using 70% ethanol. Extraction may be performed according to various extraction methods such as cold needle extraction, heat extraction, ultrasonic extraction, and cold extraction as known in the art. The extraction method is not particularly limited and may be extracted at room temperature or warmed under conditions where the active ingredient is not destroyed or minimized. In addition, as known in the art, it may be dried according to various drying methods such as hot air drying, freeze drying, and vacuum drying. Alternatively, a commercially manufactured product may be used.

In order to achieve the object of the present invention, the grape extract of the present invention is preferably a red grape extract, it is preferable to include resveratrol (Resveratrol) as an active ingredient. More preferably the grape extract contains 0.2 to 5% by weight of resveratrol. The 'resveratrol' is a polyphenol-based material (polyphenol) contained in grape skins, grape seeds, peanuts. Phytoalexin, an antibiotic made as a type of defense system when a plant faces an environment such as a fungus or pest, has been reported to have effects such as anticancer, antiviral, neuroprotection, anti-aging and life extension. In particular, it has been reported to induce metabolic activity by increasing the functionality of mitochondria through the activation of intracellular SIRT1, PGC-1α (Seung-Hoi Koo et al. Cell. 2006).

In the present invention, the 'green tea extract' can be extracted from various organs of natural, hybrid, mutant plants, for example, extractable from leaves, stems as well as plant tissue culture and according to a specific embodiment of the present invention Was used. Green tea extracts may be prepared using various solvents in a variety of ways known in the art, for example, green tea extract may include washing and drying green tea and then grinding it; And a solvent in which the pulverized green tea is mixed with one or two or more solvents selected from the group consisting of purified water, methanol, ethanol, propanol, butanol, ethylene glycol, propylene glycol, 1,3-butylene glycol, ethyl acetate, and acetone. It can be obtained including the step of extracting using. Extraction may be performed according to various extraction methods such as cold needle extraction, heat extraction, ultrasonic extraction, and cold extraction as known in the art. The extraction method is not particularly limited and may be extracted at room temperature or warmed under conditions where the active ingredient is not destroyed or minimized. In addition, as known in the art, it may be dried according to various drying methods such as hot air drying, freeze drying, and vacuum drying. According to a specific embodiment of the present invention, green tea extract was obtained from green tea leaves using purified water. In addition, green tea extract may use a commercially prepared product.

The green tea contains a large amount of catechins such as epicatechin, epicatechin galate, epigallocatechin, epigallocatechin gallate, and EGCG. It is a kind of phenol and is known to have strong antioxidant action. Therefore, green tea containing catechin has the effects of antioxidant activity, anti-inflammatory action, and the like with prevention of arteriosclerosis, cancer and nervous system diseases. In particular, the EGCG component of catechins is known to prevent the development of type 1 diabetes mellitus and to lower the blood triglycerides and low density cholesterol (LDL) to prevent adult diseases such as hyperlipidemia and arteriosclerosis.

In the present invention, the 'soy extract' can be extracted from various organs of natural, hybrid, mutant plants, for example from embryos as well as plant tissue cultures. Soybean extract can be prepared using a variety of solvents in a variety of methods known in the art, purified water, methanol, ethanol, propanol, butanol, ethylene glycol, propylene glycol, 1,3-butylene glycol, ethyl acetate, acetone One or two or more solvents selected from the composed crowd may be mixed and extracted, and according to a specific embodiment of the present invention, soybean extract was obtained through hot water extraction using purified water. Extraction may be performed according to various extraction methods such as cold needle extraction, heat extraction, ultrasonic extraction, and cold extraction as known in the art. The extraction method is not particularly limited and may be extracted at room temperature or warmed under conditions where the active ingredient is not destroyed or minimized. In addition, as known in the art, it may be dried according to various drying methods such as hot air drying, freeze drying, and vacuum drying. Alternatively, a commercially manufactured product may be used.

In order to achieve the object of the present invention, the soybean extract of the present invention preferably comprises isoflavone (Isoflavone) as an active ingredient. More preferably the soybean extract contains 0.2 to 10% by weight of isoflavones. The isoflavone is a kind of soy protein contained in soybean and has a structure similar to that of female hormone estrogen, and is known to bind to the body's estrogen receptor and activate its action. In addition, it has been reported to alleviate menopausal symptoms caused by lack of female hormones such as depression and osteoporosis.

The composite composition of the present invention is based on natural extracts such as grape extract, green tea extract, and soybean extract, which is safe, toxic, and has no side effects. In addition, the composition may be used not only in humans, but also in animals such as cattle, dogs, and the like, in which obesity-related diseases may occur.

In addition, in the present invention, carnitine may be separated from natural substances, and may be prepared by chemical synthesis by methods known in the art. The carnitine is one of the vitamin B complexes, and is an enzyme that acts to transfer fatty acids to the mitochondria in the process of breaking down fatty acids into energy. One of the two isomers of carnitine, L-carnitine, is called vitamin Bt. It has been reported that L-carnitine plays an important role in β-oxidation in mitochondria for energy production in various cells (Yano H. et al. Mol Cell Biochem, 2010), as well as CPT- which regulates fatty acid oxidation. It is used as a substrate for 1 enzyme.

Grape extract, green tea extract (and / or soybean extract), and L-carnitine in the composition according to the present invention may be included in various weight ratios as long as they can cause synergy with each other.

Preferably, the grape extract (a), green tea extract (b), and L-carnitine (c) may be contained in a ratio of a: b: c = 1 ~ 2: 1 ~ 1.2: 1, with respect to the total weight. Grape extract may be prepared to contain 0.2 to 80% by weight, green tea extract to 0.2 to 60% by weight, and L-carnitine by 0.2 to 50% by weight. If the content is less than 0.2% by weight, anti-obesity effects may be difficult to anticipate in amounts less than the recommended minimum amount. If the content is more than 80%, 60%, and 50% by weight, the amount is directly proportional to the amount used. Since the effect is not increased, it may not be suitable for economic reasons.

In addition, preferably the grape extract (a), soybean extract (b1), and L-carnitine (c) may contain a ratio of a: b1: c = 1-4: 1: 1-3, the total weight For each grape extract 0.2 to 80% by weight, soybean extract 0.2 to 80% by weight, L-carnitine may be prepared to contain 0.2 to 50% by weight. If the content is less than 0.2% by weight, anti-obesity effects may be difficult to expect in amounts less than the recommended minimum amount. If the content is more than 80%, 80%, and 50% by weight, the content is directly proportional to the amount used. Since the effect is not increased, it may not be suitable for economic reasons.

In addition, preferably the composition containing grape extract (a), green tea extract (b), soybean extract (b1), and L-carnitine (c) is a: b: b1: c = 1-4: 1-1.2: It may be contained in a ratio of 1: 1 to 3, the grape extract is 0.2 to 40% by weight, green tea extract is 0.2 to 30% by weight, soybean extract is 0.2 to 30% by weight, and L-carnitine Silver may be prepared to contain 0.2 to 40% by weight. If the content is less than 0.2% by weight, anti-obesity effects may be difficult to anticipate in amounts less than the recommended minimum amount, and if the content is more than 40%, 30%, 30%, and 40% by weight, respectively, This effect does not increase in direct proportion and may not be suitable for economic reasons.

According to a specific embodiment of the present invention, the red grape extract, green tea extract, and L-carnitine in the composition were contained in a ratio of 1: 1: 1, and were prepared to contain 33% by weight relative to the total weight (execution) Example 2). In addition, the red grape extract, soybean extract, and L-carnitine in the composition was contained in a ratio of 1: 1: 1, and was prepared to contain 33% by weight relative to the total weight (Example 3). In addition, the red grape extract, green tea extract, soybean extract, and L-carnitine in the composition was contained in a ratio of 1: 1: 1: 1, and was prepared to contain 25% by weight relative to the total weight (Example 1 ).

In addition, grape extract, green tea extract (or / and soybean extract) and L-carnitine in the composition according to the present invention may be included in various ranges of content as long as it can cause synergies with each other. For example, the grape extract, green tea extract (or soybean extract) and L-carnitine may be included in an amount of 0.6 to 100% by weight based on the total weight, but is not limited thereto. In addition, the grape extract, green tea extract, soybean extract and L-carnitine may be included in an amount of 0.8 to 100% by weight based on the total weight, but is not limited thereto. According to a specific embodiment of the present invention, in Example 1 it contained in an amount of 100% by weight based on the total weight, in Examples 2 and 3 it was included in an amount of 99.9% by weight relative to the total weight.

The anti-obesity composition according to the present invention exhibits excellent effects on weight loss, blood lipid concentration reduction, liver tissue and body fat reduction, plasma glucose concentration reduction, liver lipid improvement, and inhibition of leptin secretion, thereby preventing and treating obesity-related diseases. effective.

Accordingly, in another aspect, the present invention provides a pharmaceutical composition for preventing or treating obesity or fatty liver comprising the anti-obesity composition and a method for preventing or treating obesity or fatty liver by administering the anti-obesity composition.

As used herein, the term 'prevention' refers to any action that inhibits or delays the development of the obesity-related disease by administration of the anti-obesity composition according to the present invention.

As used herein, the term 'treatment' refers to any action in which the symptoms of the obesity-related disease are improved or beneficially changed by administration of the anti-obesity composition according to the present invention.

Compositions according to the invention can be prepared in pharmaceutical formulations using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. In the preparation of the dosage forms, it is preferred to mix or dilute the compositions according to the invention with the carrier or to enclose them in a carrier in the form of a container.

Thus, the pharmaceutical composition of the present invention in the form of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, aerosols, injectable solutions and the like according to conventional methods for preventing and treating obesity It can be formulated and used. For example, carriers, excipients and diluents which may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient in the composite composition, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. Can be prepared by mixing. In addition to the simple excipients, lubricants such as magnesium stearate, talc can also be used. Liquid preparations for oral administration include suspensions, solvents, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents, include Can be used.

Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories, and the like. As the non-aqueous solvent and the suspension solvent, vegetable oils such as propylene glycol, polyethylene glycol, olive oil, etc., injectable esters such as ethyl oleate, and the like can be used.

In addition, the pharmaceutical compositions of the present invention may further comprise a carrier, excipient or diluent. Carriers, excipients or diluents include lactose, textose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, hydroxy Minerals such as propyl methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, fluoro hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, silicon dioxide and the like can be used. have.

The dosage of the pharmaceutical composition according to the invention should be a pharmaceutically effective amount. As used herein, the term 'pharmaceutically effective amount' means an amount sufficient to prevent or treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the method of formulation, the condition and weight of the patient. It may be variously selected by those skilled in the art according to factors such as sex, age, degree of disease, type of drug, route and duration of administration, rate of excretion, response sensitivity, and the like. Effective amounts may vary depending on the route of treatment, the use of excipients, and the possibility of use with other agents, as will be appreciated by those skilled in the art. For the desired effect, in the case of oral administration, the pharmaceutical composition according to the present invention may generally be administered 1 to 500 mg, preferably 50 to 100 mg per 1 kg of body weight, which may be once to several times a day, Preferably, administration may be divided into one to three times, but the dosage and frequency do not limit the scope of the present invention in any aspect.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans and the like through various routes. All modes of administration can be expected and can be administered, for example, by oral, parenteral, intravenous, intradermal, and subcutaneous injection.

In another embodiment, the present invention provides an anti-obesity composition comprising the anti-obesity composition or

Provided is a food composition for preventing or improving fatty liver.

The food composition may be a functional food according to the purpose of the present invention, wherein the 'functional food' is a food that emphasizes the bioregulatory function of the food, and acts and expresses a specific purpose using physical, biochemical and biotechnological methods. It is food added with added value. The components of these functional foods are designed and processed to fully exercise the body's control functions related to biological defense and control of body rhythm, prevention and recovery of disease to the living body, and are acceptable food supplement additives, sweeteners or functional ingredients. It may contain.

Food compositions to which the anti-obesity composition according to the present invention can be added include, for example, various foods such as beverages, gums, teas, vitamin complexes, health supplements, and the like. Fruit juice drinks, vegetable drinks, and the like.

The food composition of the present invention may be prepared in a formulation such as tableting, tablets, granules, powders, capsules, liquid solutions, pills and the like according to known production methods. According to a specific embodiment of the present invention, capsules were prepared in Examples 4 and 5, tablets in Examples 6 and 7, and beverages were prepared in Examples 8 and 9. However, Examples 4 and 5 as a production example for producing a conventional hard capsule containing a composition for dietary intake having an anti-obesity effect, and does not limit the formulation and raw materials of the present invention. In addition, Examples 6 and 7 as a production example for producing a conventional tablet containing a composition for dietary intake having an anti-obesity effect, and does not limit the formulation and raw materials of the present invention. In addition, Examples 8 and 9 is a manufacturing example for producing a conventional beverage containing a dietary ingestion composition having an anti-obesity effect, and does not limit the formulation and raw materials of the present invention.

In addition, the food composition of the present invention may further contain conventional various flavors, natural carbohydrates and the like. Flavors include natural flavors such as tautin and stevia extract, and synthetic flavors such as saccharin and aspartame. The natural carbohydrates described above may include glucose, monosaccharides such as fructose, maltose, disaccharides such as sucrose, dextrins, polysaccharides such as cyclodextrins, sugar alcohols such as xylitol, sorbitol, erythritol, and the like. . In general, natural carbohydrates are preferably contained in a proportion of 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention. In addition, the food composition of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic or natural flavors, colorants, neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and its Salts, organic acids such as citric anhydride, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, natural fruit juices, fruit juice beverages, and pulp for making vegetable drinks It may further contain an acceptable food supplement additive. These additives may be used independently or in combination, and the ratio of the additives is not particularly limited, but may generally be appropriately selected from the range of 0 to 20 parts by weight, preferably 0.001 to 20 parts by weight, per 100 parts by weight of the composition. .

In another embodiment, the anti-obesity composition according to the present invention may be used as a cosmetic composition or quasi-drug composition for improving or preventing obesity or fatty liver.

In another aspect, the present invention provides an anti-obesity composition containing resveratrol, green tea extract, and L-carnitine as an active ingredient.

In another aspect, the present invention provides an anti-obesity composition containing resveratrol, soybean extract, and L-carnitine as an active ingredient.

In another aspect, the present invention provides an anti-obesity composition containing grape extract, isoflavone, and L-carnitine as an active ingredient.

In another aspect, the present invention provides an anti-obesity composition containing resveratrol, isoflavone, and L-carnitine as an active ingredient.

In another aspect, the present invention provides an anti-obesity composition containing resveratrol, soybean extract, green tea extract, and L-carnitine as an active ingredient.

In another aspect, the present invention provides an anti-obesity composition containing resveratrol, isoflavone, green tea extract, and L-carnitine as an active ingredient.

In another aspect, the present invention provides an anti-obesity composition containing grape extract, isoflavone, green tea extract, and L-carnitine as an active ingredient.

The 'resveratrol' and 'isoflavones' can be separated from natural substances, for example, resveratrol can be isolated from soybean isoflavone from grape extract, but is not limited thereto, or chemically known in the art It may also be produced by a synthesis method.

In another aspect, the present invention provides a pharmaceutical composition for preventing or treating obesity or fatty liver, comprising the anti-obesity composition.

In another aspect, there is provided a food composition, quasi-drug composition or cosmetic composition for improving or preventing obesity or fatty liver comprising the anti-obesity composition.

The anti-obesity composition of the present invention is expected to be effective in improving obesity, liver lipid and liver damage, thereby simultaneously preventing and treating metabolic diseases and fatty liver caused by obesity and obesity.

1 is a graph measuring the body weight after administering the complex for 8 weeks in mice inducing obesity in a high fat diet in order to confirm the weight loss effect by the anti-obesity composition according to the present invention.
2 is a result of analyzing blood lipid concentrations by collecting blood after administering the complex for 8 weeks to the mouse in order to confirm the blood lipid improving effect of the anti-obesity composition according to the present invention.
Figure 3 is a graph measuring the weight of the liver, epididymal fat, subcutaneous fat, visceral fat extracted after the administration of the complex for 8 weeks to determine the body fat reduction effect of the anti-obesity composition according to the present invention.
Figure 4 is to check the change in the blood biochemical markers by the anti-obesity composition according to the present invention, after administration of the complex for 8 weeks in mice inducing obesity in a high fat diet GOT, GPT which is an indicator of liver damage in the blood , Glucose and leptin were measured.

Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. However, these Examples and Experimental Examples are for illustrative purposes only and the scope of the present invention is not limited to these Examples.

[ Example  1] Preparation of the mixture

1-1. Preparation of Green Tea Extract

1 kg of dried green tea leaves and 23 to 30 kg of purified water were added to the extractor, and then extracted at a temperature of about 60 to 70 ° C. for about 3 hours. After the extraction was completed, the green tea leaf and its suspension were removed through a filtration apparatus and spray-dried to obtain about 250 g of green tea extract in powder form.

1-2. Preparation of Red Grape Extract

1 kg of dried red grape peel and 30 kg of 70% ethanol were added to the extractor, followed by repeated extraction for about 2 hours at a temperature of about 60 to 70 ℃. The red grape skin and its suspended matter were removed through a filtration apparatus, followed by spray drying to obtain a red grape extract in powder form. The red grape extract of the present invention contained 0.2 to 5% by weight of resveratrol.

1-3. Preparation of Soybean Extract

5 kg to 10 kg of purified water was added to 1 kg of soybean embryos, followed by stirring extraction at 80 ° C. for 2 hours. The extract thus obtained was removed through a filtration apparatus, and freeze-dried to obtain a soybean extract in powder form. The soybean extract contained isoflavones at 0.2 to 10% by weight.

1-4. Preparation of the mixture

L-carnitine was used by purchasing L-carnipure crystalline from Lonza (Basel, Switzland).

Red grape extract, green tea extract, soybean extract and L-carnitine in terms of the content ratio (unit: wt%) described in Table 1 below 25% by weight of red grape extract, 25 weight of the green tea extract prepared in 1-1 above %, Soybean extract 25% by weight, L-carnitine 25% by weight was mixed to prepare a mixture.

[ Example  2] to [ Example  3], [ Comparative example  1] to [ Comparative example  8]

As shown in Table 1 below, the red grape extract, green tea extract, soybean extract and L-carnitine in the same manner as in Example 1 was changed only to prepare a mixture.

Red grape extract
(weight%) Green tea extract
(weight%) Soybean Extract
(weight%) L-carnitine
(weight%) Example 1 25 25 25 25 Example 2 33.3 33.3 0 33.3 Example 3 33.3 0 33.3 33.3 Comparative Example 1 33.3 33.3 33.3 0 Comparative Example 2 50 50 0 0 Comparative Example 3 50 0 50 0 Comparative Example 4 50 0 0 50 Comparative Example 5 100 0 0 0 Comparative Example 6 0 100 0 0 Comparative Example 7 0 0 100 0 Comparative Example 8 0 0 0 100

[ Experimental Example  1] using mouse Red grapes  Extract, green tea extract, soybean extract and L- Carnitine  Determine the weight loss effect of the complex

In order to determine the effect of the composition of the present invention on lipid metabolism of the obese-induced animal model in a high-fat diet, experiments were conducted on 100 male C57BL / 6 mice. Obesity was induced by 7 weeks old C57BL / 6 mice by autonomous feeding of high fat diet for 3 weeks, and randomly distributed to each group by equal distribution of 7 animals. Each group 600 mg of the mixture of Examples 1 to 3, Comparative Examples 1 to 8 prepared in the ratio of Table 1 together with the control group 1 fed a normal feed, the control 2 fed a high fat feed, high fat feed The treatment group (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11) orally administered at a dose of / day / kg was divided into 13 groups. For treatment groups (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11), the mixture was dosed according to the weight average of each group using a feeding needle for mice. Calculation and oral administration. In the case of control group 2, pure water was orally administered to set the medium control group. Oral administration was performed at the same time period every day for a total of 8 weeks over 6 days a week.

Animal feed was used as a solid feed for laboratory animals (Harlan, Supplier; Polars International Co., Ltd.) during the period of purification and quarantine, and high-fat diets made up of 60% of the total calories during administration and observation. 60% Kcal, Research Diets, supplier: central laboratory animals).

All animals were weighed twice a week at the start of administration and immediately before administration during the test period, and the change in body weight after the end of 8 weeks of administration was calculated and shown in Table 2 and FIG. 1.

Classification % Weight gain Standard Deviation IR (%) Control group 1 Normal feed 113.2 ± 5.8 Control 2 High Fat Feed 148.4 ± 9.1 Treatment Group 1 Example 1 115.8 ± 9.6 22.0 *** Treatment Group 2 Example 2 117.5 ± 12.7 20.8 *** Treatment Group 3 Example 3 125.2 ± 11.8 15.6 ** Treatment Group 4 Comparative Example 1 134.5 ± 15.2 9.4 Treatment Group 5 Comparative Example 2 131.9 ± 12.5 11.1 Treatment Group 6 Comparative Example 3 133.5 ± 7.6 10.0 Treatment group 7 Comparative Example 4 132.4 ± 6.6 10.8 * Treatment Group 8 Comparative Example 5 144.5 ± 8.3 2.6 Treatment group 9 Comparative Example 6 140.4 ± 11.3 5.4 Treatment group 10 Comparative Example 7 140.5 ± 10.4 5.3 Treatment Group 11 Comparative Example 8 138.3 ± 8.9 6.8 *

① Significant (t-TEST): * p <0.05, ** p <0.01, *** p <0.001 vs Control 2

② IR (%): Inhibition rate, 100- [(Treatment / Control 2) * 100]

As a result, as shown in Table 2, the weight of the high fat feed control group 2 was significantly increased compared to the normal feed control group 1, and it was confirmed that obesity caused by diet was effectively induced (p <0.05).

There was no difference in body weight before the start of the experiment, because obesity was induced for 3 weeks with high-fat diet and then evenly distributed to each group. After 8 weeks of administration, weight loss was observed in common, and there was a difference in weight gain and inhibition rate according to each mixture.

Specifically, the treatment group 1 (red grape extract + green tea extract + soybean extract + L-carnitine) in which all four substances were mixed showed a significant weight loss effect of about 22.0% compared to the control group (p <0.001). In the treatment group 2 (red grape extract + green tea extract + L-carnitine) and the treatment group 3 (red grape extract + soybean extract + L-carnitine), which were mixed with three of the four substances, about 20.8%, respectively, A significant weight loss effect of 15.6% was identified (p <0.05).

However, in the treatment group 4 (red grape extract + green tea extract + soybean extract) in the combination of three of the four substances and the treatment groups 5, 6, and 7 in which the two substances were mixed, each component was administered alone. Compared to one treatment group 8, 9, 10, and 11 showed an increased efficacy, except for the treatment group 7, it was not a significant value and only tendency could be confirmed. In addition, the treatment group 8, 9, 10, 11 administered only a single substance did not show a significant weight loss effect (p> 0.05).

From these experimental results, when all four components of red grape extract, green tea extract, soybean extract, and L-carnitine were mixed, synergistic effects appeared between the components, and it was confirmed that weight gain by high fat diet can be effectively suppressed. It was. In addition, the combination of three components of red grape extract, L-carnitine and green tea extract or soybean extract showed an increased effect on inhibiting obesity. The effect was better in one treatment group 2. In contrast, the combination of treatment group 4 did not show elevated anti-obesity efficacy. This indicated that specific synergistic effects may occur when red grape extracts interact with green tea extract (or / and soybean extract) and L-carnitine in combination.

The best weight loss in the combination of four substances (red grape extract + green tea extract + soybean extract + L-carnitine) as a result of the administration of four substances in a concentration range of low efficacy as a single substance in various combinations Efficacy was shown, which was a synergistic effect due to the synergy of each of the substances. In addition, the combination of three substances, red grape extract + green tea extract (or soybean extract) + L-carnitine combination showed an excellent weight loss phenomenon, synergistic effect when each of the combinations It has been shown that elevated efficacy can be exerted through.

[ Experimental Example  2] Red grapes  Extract, green tea extract, soybean extract and L- Carnitine  Reduction of Blood Lipid Levels by Complexes

The blood of the mice before the start of administration and the blood after the end of the administration for 8 weeks were collected from the mice of Experimental Example 1. The collected blood was heparinized to obtain plasma by centrifugation. Using a measurement kit (Dong Young Pharm.), Blood triglyceride (TG), total cholesterol (cholesyterol, TC) and LDL (low density) were used. lipoprotein) -cholesterol (hereinafter, LDL-c) levels were measured. The results are shown in Table 3 and FIG. 2, and the values of the lipid indexes measured in blood before the start of administration were expressed in terms of 100.

Classification TG TC LDL-c Average Standard Deviation Average Standard Deviation Average Standard Deviation Control group 1 Normal feed 56.3 ± 11 106 ± 27.8 9 ± 2.1 Control 2 High Fat Feed 69 ± 8.5 175 ± 11.7 11.7 ± 3.7 Treatment Group 1 Example 1 22.4 ** ± 9.2 117.5 ** ± 20.4 5.7 * ± 3.0 Treatment Group 2 Example 2 34.5 * ± 6.9 134.5 ± 8.2 7.5 * ± 2.9 Treatment Group 3 Example 3 45.7 * ± 4.1 133.4 ± 23.8 6.9 * ± 2.4 Treatment Group 4 Comparative Example 1 57.5 ± 3.5 168.5 ± 15.4 10.5 ± 1.1 Treatment Group 5 Comparative Example 2 55.8 ± 14.1 159.8 ± 18.5 12.5 ± 3.2 Treatment Group 6 Comparative Example 3 62.4 ± 12.4 186.4 ± 20.7 10.2 ± 2.2 Treatment group 7 Comparative Example 4 69.2 ± 12.3 179.8 ± 13.8 11.6 ± 1.2 Treatment Group 8 Comparative Example 5 63.5 ± 5.7 168.9 ± 10.4 12.8 ± 1.8 Treatment group 9 Comparative Example 6 65.3 ± 2.3 183 ± 26.7 13.6 ± 2.6 Treatment group 10 Comparative Example 7 59.8 ± 6.7 179.5 ± 30.8 11.2 ± 4.8 Treatment Group 11 Comparative Example 8 69.7 ± 10.6 185.7 ± 17.9 11.4 ± 3.8

① Significant (t-TEST): * p <0.05, ** p <0.01, *** p <0.001 vs Control 2

② IR (%): Inhibition rate, 100- [(Treatment / Control 2) * 100]

As a result of the experiment, in the treatment group 1 (red grape extract + green tea extract + soybean extract + L-carnitine) mixed with all four substances, the blood TG, TC and LDL-c levels were all significantly reduced compared to the control group 2. (P <0.05). Specifically, compared to the control group 2, which was fed high fat feed, the TG level was 67.5%, the TC level was 32.8%, and the LDL-c level was 51.3%. The effect was confirmed. Blood TG and LDL-c levels were significantly higher in the treatment group 2 (red grape extract + green tea extract + L-carnitine) and the treatment group 3 (red grape extract + soybean extract + L-carnitine). It was decreased (p <0.05) and blood TC was found to be decreased (p> 0.05). In the treatment group 2 (red grape extract + green tea extract + L-carnitine) mixed with green tea extract, the blood TG level decreased by 50% compared to the control group 2, and the treatment group 3 (red grape extract + soybean mixed with soybean extract) Extract + L-carnitine) showed an inhibition rate of 41% of blood LDL-c levels.

Treatment Group 4 (Red Grape Extract + Green Tea Extract + Soybean Extract) and Treatment Group 5 (Red Grape Extract + Green Tea Extract) in which the two substances were mixed, Treatment Group 6 (Red Grape Extract + Soybean Extract), Treatment Group 7 (Red) In case of treatment group 8 (red grape extract), treatment group 9 (green tea extract), treatment group 10 (soybean extract) and treatment group 11 (L-carnitine), which were treated with grape extract + L-carnitine) alone, One did not show a blood lipid-improving effect.

Through the above experimental results, when a single substance was treated with a low concentration of four substances (red grape extract, green tea extract, soybean extract, L-carnitine) that showed little or no effect, It was confirmed that synergistic efficacy appeared. When the complex containing all four substances was treated, it showed the best blood lipid improving effect. Even if the red grape extract acted in combination with green tea extract (or soybean extract) and L-carnitine, blood TG, LDL- c Excellent effect on improvement.

[ Experimental Example  3] Red grapes  Extract, green tea extract, soybean extract and L- Carnitine  Reduced Body Fat by Complex

After 8 weeks of administration, the mouse of Experiment 1 was autopsied to examine liver tissue, epididymal adipose tissue, subcutaneous adipose tissue, mesentric adipose tissue, and perirenal adipose tissue. ) The tissue was extracted and weighed. The extracted tissues were washed with physiological saline and water was removed to determine the weight, and the average of each treatment group was calculated and shown in Table 4 and FIG. 3.

Classification Liver (g) Epididymal Fat (g) Subcutaneous
Fat (g) guts
Fat (g) Control group 1 Normal feed 1071.1 ± 160.9 478.5 ± 208.5 438.3 ± 164.9 132.2 ± 78.6 Control 2 High Fat Feed 1643.6 ± 330.6 2688.2 ± 379.5 3512.4 ± 848.4 1151 ± 147.1 Treatment Group 1 Example 1 1045.8 ± 123.4
*** 1856.2 ± 152.6
** 2556.2 ± 568.4
* 985.1 ± 51.5
* Treatment Group 2 Example 2 1063.5 ± 186.5
** 2213.5 ± 295.3
* 2956.5 ± 315.6 951.2 ± 126.5
* Treatment Group 3 Example 3 1246.5 ± 200.7
* 1956.7 ± 165.9
** 2965.4 ± 485.9 1015.1 ± 46.5
* Treatment Group 4 Comparative Example 1 1486 ± 180.7 2456.9 ± 201.1 3365.7 ± 102.4 1190.6 ± 75.4 Treatment Group 5 Comparative Example 2 1356.4 ± 300.4 2568.2 ± 300.4 3265.6 ± 235.1 1265.4 ± 95.1 Treatment Group 6 Comparative Example 3 1548.9 ± 358.1 2246.4 ± 264.0 3025.5 ± 265.7 1156.5 ± 115.3 Treatment group 7 Comparative Example 4 1514.6 ± 112.5 2653.2 ± 325.4 3459.2 ± 112.1 1200.4 ± 132.2 Treatment Group 8 Comparative Example 5 1653.7 ± 52.6 2689.5 ± 296.6 3326.4 ± 346.2 1321.1 ± 95.1 Treatment group 9 Comparative Example 6 1698.2 ± 135.4 2756.4 ± 125.5 3259.8 ± 118.5 1256.2 ± 86.2 Treatment group 10 Comparative Example 7 1594.5 ± 267.5 2698.4 ± 295.3 3568.9 ± 124.6 1145.8 ± 153.2 Treatment Group 11 Comparative Example 8 1602.5 ± 382.2 2956.8 ± 185.3 3425.1 ± 132.4 1065.9 ± 56.1

① Significant (t-TEST): * p <0.05, ** p <0.01, *** p <0.001 vs Control 2

② IR (%): Inhibition rate, 100- [(Treatment / Control 2) * 100]

As shown in Table 4, the treatment group 1 (red grape extract + green tea extract + soybean extract + L-carnitine) containing all four substances had liver tissue, epididymal fat, subcutaneous fat and visceral fat as compared to the control group 2. All decreased significantly (p <0.05). Specifically, liver tissue weight showed an inhibition rate of 36.4% of fat accumulation compared to Control 2, and 30.9% of epididymal fat, 27.2% of subcutaneous fat, and 14.4% of visceral fat showed excellent body fat suppression effect.

In the combination of three substances, treatment group 2 (red grape extract + green tea extract + L-carnitine) and treatment group 3 (red grape extract + soybean extract + L-carnitine) were treated with liver tissue, epididymal fat and visceral fat. The weight of was significantly reduced. Treatment group 2 containing green tea extract was more effective in reducing liver tissue and visceral fat, and treatment group 3 containing soybean extract showed excellent efficacy in inhibiting epididymal fat accumulation. Treatment group 4 (red grape extract + green tea extract + soybean extract) of the combination of three substances, treatment group 5 (red grape extract + green tea extract), which mixed two substances, treatment group 6 (red grape extract + soybean) Extract), treatment group 7 (red grape extract + L-carnitine) and treatment group 8 (red grape extract), treatment group 9 (green tea extract), treatment group 10 (soy extract), treatment group 11 ( L-carnitine) showed no significant weight loss.

 Experimental results, as confirmed through the results of Experimental Examples 1 and 2 as a single was able to verify that the increased potency appeared when mixing four materials in the concentration range of the efficacy is insignificant. In addition, it was confirmed that a complex of three substances in which red grape extract and L-carnitine was mixed with either green tea extract or soybean extract was effective in reducing liver tissue and body fat.

[ Experimental Example  4] Red grapes  Extract, green tea extract, soybean extract and L- Carnitine  Determination of Blood Biochemical Changes by Complex Treatments

All mice of Experimental Example 1 were collected by orbital blood collection at the end of the administration. The collected blood was centrifuged after heparin treatment to obtain plasma, and GOT (Aspartate aminotransferase (AST), GPT, which is an indicator of glucose and liver damage in blood using a biochemical automatic analyzer (AU400, Olympus, Japan). Alanine aminotransferase (ALT) was measured. In addition, plasma levels of Leptin, a hormone produced by the fat cell's obesity gene, which inhibited food intake and increased energy consumption, were measured using a kit using the Enzyme Liked Immunosolvent assay (ELISA) principle.

Plasma glucose concentrations were significantly increased in control group 2 fed high fat diet and significantly decreased in treatment group 1 (red grape extract + green tea extract + soybean extract + L-carnitine) containing all four substances. Appeared. In the plasma GOT and GPT levels, significant decreases were observed in the treatment group 2 and 3 of the combination of the four substances (treatment group 1) and the combination of the three substances. In particular, it was confirmed that the treatment group 2 (red grape extract + green tea extract + L-carnitine) has an excellent effect of inhibiting the GPT level by about 45% (p <0.05).

Plasma Leptin levels were significantly increased by high-fat diet intake (p <0.05), and leptin was secreted by Group 2 (Red Grape Extract + Green Tea Extract + L-Carnitine). Was found to be most effectively suppressed (p <0.05). Specifically, about 33.7% of the secretion of leptin was suppressed in the treatment group 2, and the result is shown in FIG. 4.

[ Example  4] ~ [ Example  5] Capsule  Produce

Red Grape Extract, Green Tea Extract, and L-Carnitine (Example 4) or Red Grape Extract, Green Tea Extract, Soybean Extract, and L-Carnitine (Example 5) are excipients commonly used in hard capsules. Hard capsules were prepared in the combinations and amounts shown in Table 5 using silicon dioxide and magnesium stearate.

ingredient Example 4 Example 5 Compounding ratio (% by weight) Content (mg) Compounding ratio (% by weight) Content (mg) Red grape extract 32.0 160.0 24.5 122.5 Green tea extract 33.0 165.0 24.5 122.5 L-carnitine 33.0 165.0 24.5 122.5 Soybean Extract - - 24.5 122.5 Silicon dioxide 1.0 5.0 1.0 5.0 Magnesium stearate 1.0 5.0 1.0 5.0 Sum 100 500 100 500

As shown in Table 5, red grape extract, green tea extract, and L-carnitine or red grape extract, green tea extract, soybean extract, and a mixture of L-carnitine and excipients were uniformly stirred and granulated. This was injected into a hard capsule machine to prepare a conventional hard capsule.

[ Example  6] ~ [ Example  7] tablet manufacturing

Lactose extract, green tea extract, and L-carnitine (Example 6) or lactose extract, green tea extract, soybean extract, and L-carnitine (Example 7) as main ingredients and lactose, an excipient commonly used in tablets Tablets were prepared in the combinations and amounts shown in Table 6 using powders, crystalline cellulose, magnesium stearate and hydroxy propyl methyl cellulose (HPMC).

ingredient Example 6 Example 7 Compounding ratio (% by weight) Content (mg) Compounding ratio (% by weight) Content (mg) Red grape extract 20.0 100.0 15.0 75.0 Green tea extract 20.0 100.0 15.0 75.0 L-carnitine 20.0 100.0 15.0 75.0 Soybean Extract - - 15.0 75.0 Lactose powder 18.0 90.0 18.0 90.0 Crystalline cellulose 20.0 100.0 20.0 100.0 Magnesium stearate 1.0 5.0 1.0 5.0 HPMC 1.0 5.0 1.0 5.0 Sum 100 500 100 500

As shown in Table 6, red grape extract, green tea extract, and L-carnitine or red grape extract, green tea extract, soybean extract, and a mixture of L-carnitine and excipients were uniformly stirred and granulated. It was injected into a tablet press to prepare a tablet of the passbook.

[ Example  8] ~ [ Example  9] Beverage Manufacturing

Red carbohydrate extract, green tea extract, and L-carnitine (Example 8) or red grape extract, green tea extract, soybean extract, and L-carnitine (Example 9) as a main component, and natural carbohydrates commonly used in beverages Drinks were prepared in the combinations and amounts shown in Table 7 using food supplement additives, fructose, citric anhydride, vitamin C, and purified water.

ingredient Example 8 Example 9 Compounding ratio (% by weight) Compounding ratio (% by weight) Red grape extract 1.4 1.05 Green tea extract 1.4 1.05 L-carnitine 1.4 1.05 Soybean Extract - 1.05 Fructose 10.0 10.0 Citric anhydride 0.4 0.4 Vitamin c 0.1 0.1 Purified water 85.3 85.3 Sum 100.0 100.0

As shown in Table 7, the mixture of red grape extract, green tea extract, and L-carnitine or red grape extract, green tea extract, soybean extract, and L-carnitine and excipients were mixed uniformly using a high speed stirrer, followed by purified water Was added to uniformly mix. And the mixture was subjected to high temperature sterilization and put into a bottle or can to prepare a beverage.

Claims (23)

Anti-obesity composition containing at least one selected from the group consisting of green tea extract and soybean extract and red grape extract and L-carnitine as an active ingredient.
The anti-obesity composition according to claim 1, wherein the red grape extract contains resveratrol.
The anti-obesity composition of claim 1, wherein the soybean extract contains isoflavones.
2. The anti-obesity composition of claim 1, wherein the green tea extract is extracted from green tea leaves.
The anti-obesity composition according to claim 1, wherein the extraction solvent of the green tea extract is purified water.
The anti-obesity composition according to claim 1, wherein the red grape extract is extracted from a red grape peel.
The anti-obesity composition according to claim 1, wherein the extraction solvent of the red grape extract is ethanol.
The anti-obesity composition of claim 1, wherein the soybean extract is extracted from soybean embryos.
The anti-obesity composition according to claim 1, wherein the extraction solvent of the soybean extract is purified water.
The anti-obesity composition according to claim 1, wherein the red grape extract: green tea extract: L-carnitine is contained in a weight ratio of 1 to 2: 1 to 1.2: 1.
The anti-obesity composition according to claim 1, wherein the red grape extract: soybean extract: L-carnitine is contained in a weight ratio of 1-4: 1: 1-3.
The anti-obesity composition according to claim 1, wherein the red grape extract: green tea extract: soybean extract: L-carnitine is contained in a weight ratio of 1 to 4: 1 to 1.2: 1 to 1 to 3.
The anti-obesity composition according to claim 1, wherein the red grape extract contains 0.2 to 80 wt%, the green tea extract is 0.2 to 60 wt%, and the L-carnitine is 0.2 to 50 wt% based on the total weight of the composition. .
The anti-obesity composition according to claim 1, wherein the red grape extract contains 0.2 to 80% by weight, soybean extract is 0.2 to 80% by weight, and L-carnitine is 0.2 to 50% by weight based on the total weight of the composition. .
The method of claim 1, wherein the red grape extract is 0.2 to 40% by weight, green tea extract is 0.2 to 30% by weight, soybean extract is 0.2 to 30% by weight, and L-carnitine is 0.2 to 40% by weight based on the total weight of the composition An anti-obesity composition, characterized in that it contains.
The anti-obesity composition according to claim 1, wherein the green tea extract, soybean extract, red grape extract, and L-carnitine are contained in an amount of 0.6 to 100% by weight based on the total weight.
The anti-obesity composition according to claim 1, wherein the green tea extract, soybean extract, red grape extract, and L-carnitine are contained in an amount of 0.8 to 100% by weight based on the total weight.
A pharmaceutical composition for preventing or treating obesity or fatty liver comprising the anti-obesity composition of any one of claims 1 to 17.
19. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, aerosols and injectable solutions. Pharmaceutical compositions.
19. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is any one pharmaceutically acceptable carrier selected from the group consisting of oral, intravenous, intramuscular or subcutaneous injection administration.
A food composition for preventing or improving obesity or fatty liver comprising the anti-obesity composition of any one of claims 1 to 17.
The food composition of claim 21, wherein the food composition is any one formulation selected from the group consisting of tablets, granules, powders, capsules, liquid solutions, and pills.
The food composition of claim 21, wherein the food composition further comprises any one or more selected from the group consisting of flavoring agents, natural carbohydrates, food acceptable food additive additives, carriers, excipients and diluents. .

Images